Dr. Reddy''s Laboratories Ltd.

NSE: DRREDDY BSE: 500124 SECTOR: Pharmaceuticals & Drugs  89k   830   104

4496.15
-95.40 (-2.08%)
NSE: 21 Jan 03:59 PM

Price Summary

Today's High

₹ 4570

Today's Low

₹ 4435

52 Week High

₹ 5614.6

52 Week Low

₹ 4135

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

74823.53 Cr.

Enterprise Value

74731.73 Cr.

No. of Shares

16.64 Cr.

P/E

46.26

P/B

4.28

Face Value

₹ 5

Div. Yield

0.56 %

Book Value (TTM)

₹  1049.62

CASH

1306.3 Cr.

DEBT

1214.5 Cr.

Promoter Holding

26.72 %

EPS (TTM)

₹  97.2

Sales Growth

12.65%

ROE

13.69 %

ROCE

17.81%

Profit Growth

-25.57 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Dr. Reddy''s Laboratories Ltd.

Molflu OMEZ Nise Stamlo Clamp Econorm Razo SENQUEL-F KETOROL ATOCOR MINTOP VENUSIA Glimy Telsartan Activ

Index Presence

The company is present in 34 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year12.65%
3 Year12.56%
5 Year5.34%

Profit Growth

1 Year-25.57%
3 Year56.82%
5 Year9.73%

ROE%

1 Year13.69%
3 Year15.13%
5 Year12.41%

ROCE %

1 Year17.81%
3 Year16.29%
5 Year13.05%

Debt/Equity

0.072

Price to Cash Flow

21.29

Interest Cover Ratio

66.4432548179872

CFO/PAT (5 Yr. Avg.)

1.27747713232125

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2021 26.72 0
Sep 2021 26.72 0
Jun 2021 26.73 0
Mar 2021 26.74 0
Dec 2020 26.73 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 56.822264436488% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 66.4432548179872.
  • Company has a healthy liquidity position with current ratio of 2.3998859724141.
  • The company has a good cash flow management; CFO/PAT stands at 1.27747713232125.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 5.25006049490999.

 Limitations

  • The company has shown a poor revenue growth of 12.5648696393281% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 3345.8 3408.2 3350.7 3433.5 3823.4
Total Expenditure 2529.2 2634.2 2747.8 2871.6 3075.1
Operating Profit 816.6 774 602.9 561.9 748.3
Other Income 26.6 62.8 81.6 186.2 118.1
Interest 9.3 6.5 16.9 6.5 11.1
Depreciation 214.2 212.4 210.7 197.1 206.6
Exceptional Items 0 0 0 0 0
Profit Before Tax 619.7 617.9 456.9 544.5 648.7
Tax 138.7 174.2 145.4 131.1 199.7
Profit After Tax 481 443.7 311.5 413.4 449
Adjusted EPS (Rs) 28.94 26.7 18.72 24.84 26.98

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 9719.8 9359.3 10625.5 11850.4 13349.1
Total Expenditure 8041.2 8086.7 8360.9 8980.8 10212.3
Operating Profit 1678.6 1272.6 2264.6 2869.6 3136.8
Other Income 658.2 261.3 273.5 743.2 801.1
Interest 57.2 62.8 56.8 47.8 46.7
Depreciation 735.1 774.1 780.6 789.2 835
Exceptional Items 0 0 0 0 0
Profit Before Tax 1544.5 697 1700.7 2775.8 3056.2
Tax 160.4 130.1 423.4 -161.9 869.8
Net Profit 1384.1 566.9 1277.3 2937.7 2186.4
Adjusted EPS (Rs.) 83.48 34.15 76.95 176.76 131.39

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 82.9 83 83 83.1 83.2
Total Reserves 11517.7 11724.8 12601.1 15108.8 16900.5
Borrowings 485.2 488 345.4 19.3 17.7
Other N/C liabilities 21.3 -8.5 138.7 -528.8 -186.9
Current liabilities 4258 4719.9 3079.3 4180.5 4560.3
Total Liabilities 16365.1 17007.2 16247.5 18862.9 21374.8
Assets
Net Block 4842.1 4717.3 4682.7 4433.9 5844.3
Capital WIP 540 675 400.1 384.1 877.1
Intangible WIP 0 0 0 27.7 23.7
Investments 1802.8 1953.7 1819.1 3367.1 3392.2
Loans & Advances 581.7 620.1 407 542 293.2
Other N/C Assets 4.7 2.6 5.4 1.4 0.1
Current Assets 8593.8 9038.5 8933.2 10106.7 10944.2
Total Assets 16365.1 17007.2 16247.5 18862.9 21374.8
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 1544.5 697 1700.7 2775.8 3056.2
Adjustment 648.3 964.3 958.1 681.8 273.3
Changes in Assets & Liabilities -854.1 51.3 342.1 -1141.5 632.7
Tax Paid -322.8 -174 -238.8 -476.9 -448
Operating Cash Flow 1015.9 1538.6 2762.1 1839.2 3514.2
Investing Cash Flow 1430.5 -1180.2 -546.5 -1689.2 -1453.6
Financing Cash Flow -2581.8 -304.4 -2223.1 -224.1 -794.3
Net Cash Flow -135.4 54 -7.5 -74.1 1266.3

Corporate Actions

Investors Details

PARTICULARS Dec 2020% Mar 2021% Jun 2021% Sep 2021% Dec 2021%
Promoters 26.73 26.74 26.73 26.72 26.72
g.v.prasad - - 0.71 0.71 0.75
samrajyam reddy ka... 0.67 0.67 0.67 0.67 0.67
gunupati venkatesw... 0.67 0.67 - - -
satish reddy kallam 0.54 0.54 0.61 0.61 0.61
PARTICULARS Dec 2020% Mar 2021% Jun 2021% Sep 2021% Dec 2021%
Investors 73.27 73.26 73.27 73.28 73.28
jp morgan chase ba... - - - 13.31 14.35
jp morgan chase ba... 12.05 - 13.41 - -
life insurance cor... - - 3.51 4.44 -
life insurance cor... 4.50 4.91 - - -
life insurance cor... - - - - 4.44
first senter inves... 3.37 3.37 - - -
first state invest... - - 3.24 3.24 3.24
oppenheimer develo... - - 3.19 3.19 -
franklin templeton... - - 2.08 2.91 2.87
sbi mutual fund 2.12 - - - -
first state invest... - - 1.17 1.17 1.55
reliance capital t... - - - 2.08 2.57
franklin templeton... - - - 1.83 2.29
aditya birla sun l... - - 1.67 1.75 2.23
sbi-etf nifty 50 - 2.41 - - -
reliance capital a... - - 2.38 - -
aditya birla mutua... 1.91 - - - -
aditya birla sun l... - 1.91 - - -
mirae asset mutual... 1.42 - - - -
government of sing... 1.70 1.71 - - -
franklin templeton... - - 1.75 - -
icici prudential l... 1.06 1.47 - - -
government of sing... - - - - -
nps trust-a/c hdfc... 1.27 1.41 - - -
icici prudential f... - - - - 1.31
nps trust - a/c - - - - -
uti-mastershare un... - 1.24 - - -
nps trust- a/c - - - - -
dsp mutual fund 1.09 - - - -
mirae asset tax sa... - 1.22 - - -
teluk kemang inves... - - 1.21 1.21 1.21
uti mutual fund 1.16 - - - -
icici prudential s... - 1.03 - - -
iepf 0.14 0.14 0.07 0.07 0.07

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Dr. Reddy’s Laboratories informs about press release17 Jan 2022, 4:29PM Dr. Reddy’s partners with UoH for developing cold chain logistics solutions for pharmaceutical firms7 Jan 2022, 12:45PM Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment 5 Jan 2022, 9:27AM Dr. Reddy's Laboratories to introduce Molnupiravir in India to treat Covid-1929 Dec 2021, 12:38PM Dr. Reddy's gets USFDA’s approval for ANDA VeraRing11 Dec 2021, 10:13AM Dr.Reddy's Laboratories informs about press release10 Dec 2021, 12:42PM Dr. Reddy's launches Venlafaxine ER Tablets in US Market10 Dec 2021, 9:13AM Dr. Reddy’s launches Valsartan Tablets in US Market9 Dec 2021, 12:14PM Dr. Reddy’s Laboratories informs about press release9 Dec 2021, 9:53AM Dr. Reddy’s enters into binding agreement with Prestige BioPharma 9 Dec 2021, 9:07AM Dr. Reddy's Laboratories informs about transcript of the earnings call6 Nov 2021, 11:49AM Dr Reddys Laboratories informs about earnings call30 Oct 2021, 11:36AM Dr. Reddy’s launches Ephedrine Sulfate Injection in US market30 Oct 2021, 8:51AM Dr. Reddy's Laboratories informs about loss of share certificate23 Oct 2021, 10:05AM Dr. Reddy's Laboratories informs about press release19 Oct 2021, 9:54AM Dr. Reddy’s gets USFDA’s final approval for Lenalidomide Capsules 19 Oct 2021, 9:29AM Dr. Reddy's Laboratories informs about press release16 Oct 2021, 10:59AM Dr. Reddy's launches Carmustine for Injection, USP in US market16 Oct 2021, 8:47AM Dr Reddys Laboratories informs about loss of share certificate7 Oct 2021, 9:41AM Dr. Reddy's Laboratories starts supply of Sputnik V first doses to partner hospitals8 Sep 2021, 11:44AM Dr. Reddy's Laboratories launches Minoxidil for women 7 Sep 2021, 1:16PM Dr. Reddy's Laboratories informs about press release4 Sep 2021, 12:11PM Dr. Reddy's Laboratories enters into definitive agreement with Citius Pharmaceuticals4 Sep 2021, 11:37AM Dr. Reddy's Laboratories informs about press release2 Sep 2021, 10:04AM Dr. Reddy's Laboratories launches Reddy-Lenalidomide in Canadian market2 Sep 2021, 9:15AM Dr. Reddy's Laboratories launches Chlordiazepoxide Hydrochloride, Clidinium Bromide Capsules31 Aug 2021, 12:06PM Dr. Reddy's Laboratories’ arm recalling 37,560 bottles of Tizanidine HCl tablets31 Aug 2021, 11:26AM Dr Reddy's enters into definitive agreement with BioDelivery Sciences International5 Aug 2021, 9:41AM Dr Reddy's re-launches over-the-counter Naproxen Sodium Tablets 4 Aug 2021, 9:17AM Dr Reddy's anticipates locally manufactured Sputnik V to be available from September-October period28 Jul 2021, 12:45PM Dr Reddys Laboratories informs about disclosure28 Jul 2021, 11:35AM Dr. Reddy's Laboratories reports 36% fall in Q1 consolidated net profit27 Jul 2021, 3:59PM Dr.Reddy's Laboratories informs about board meeting proceedings27 Jul 2021, 2:06PM Dr. Reddy's Laboratories’ business growth to be volatile in FY225 Jul 2021, 12:11PM Dr Reddy’s Laboratories submits annual report3 Jul 2021, 11:21AM Cipla, Dr. Reddy’s, Emcure, Sun Pharma and Torrent to collaborate for clinical trial of Molnupiravir for COVID-19 30 Jun 2021, 1:00PM Dr. Reddy's Laboratories partners with B Medical Systems29 Jun 2021, 2:41PM Dr. Reddy's Laboratories informs about press release28 Jun 2021, 9:33AM Dr. Reddy's Laboratories launches 2-deoxy-D-glucose28 Jun 2021, 9:13AM Dr Reddy's Laboratories informs about press release22 Jun 2021, 10:05AM Dr. Reddy's Laboratories launches Icosapent Ethyl Capsules22 Jun 2021, 9:20AM Dr Reddy's Laboratories ordered to pay $46.25 million to Hatchtech16 Jun 2021, 2:34PM Dr Reddys Laboratories informs about issue of duplicate share certificates10 Jun 2021, 12:16PM Dr. Reddy's Laboratories inks pact with Rockwell Industries10 Jun 2021, 11:33AM Dr. Reddy's recalling 2,980 bottles of Atorvastatin Calcium tablets in US7 Jun 2021, 10:31AM Dr Reddy's Laboratories earmarks capex of around Rs 1,000 crore for current fiscal 24 May 2021, 1:14PM Dr Reddys Laboratories informs about newspaper advertisement24 May 2021, 10:38AM Dr. Reddy's working on development of new treatment options for COVID-19 patients24 May 2021, 9:01AM Dr. Reddy's Laboratories, Apollo Hospitals enter into partnership for COVID-19 vaccination 17 May 2021, 5:06PM Dr. Reddys Laboratories informs about newspaper publication15 May 2021, 4:48PM

Dr. Reddy''s Lab Stock Price Analysis and Quick Research Report. Is Dr. Reddy''s Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Reddy''s Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 3514.2 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Reddy''s Lab has a Debt to Equity ratio of 0.072 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Reddy''s Lab , the EPS growth was -25.6638827863766 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Reddy''s Lab has OPM of 23.4982133626986 % which is a good sign for profitability.
     
  • ROE: Dr. Reddy''s Lab have a average ROE of 13.6884414559934 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Dr. Reddy''s Lab

X